Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

« Previous Next »American Heart Journal
Volume 159, Issue 3 , Pages 331-339, March 2010

Renato D. Lopes, MD, PhD
- Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
John H. Alexander, MD, MHS
- Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Sana M. Al-Khatib, MD, MHS
- Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Jack Ansell, MD
- Lenox Hill Hospital, New York, NY
Raphael Diaz, MD
- Estudios Cardiologicos Latinoamerica, Santa Fe, Argentina
J. Donald Easton, MD
- Rhode Island Hospital, Alpert Medical School, Brown University, Providence, RI
Bernard J. Gersh, MB, ChB, DPhil
- Mayo Clinic College of Medicine, Rochester, MN
Christopher B. Granger, MD
- Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
- Reprint requests: Christopher B. Granger, MD, Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707.
Michael Hanna, MD
- Bristol-Myers Squibb, Princeton, NJ
John Horowitz, MD
- University of Adelaide, Adelaide, Australia
Elaine M. Hylek, MD, MPH
- Boston University Medical Center, Boston, MA
John J.V. McMurray, MD
- Western Infirmary, Glasgow, United Kingdom
Freek W.A. Verheugt, MD, PhD
- University Medical Center, Nijmegen, The Netherlands
Lars Wallentin, MD, PhD
- Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
on behalf of the ARISTOTLE Investigators